{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:03:44Z","timestamp":1792451024469,"version":"4.5.0"},"reference-count":102,"publisher":"Bentham Science Publishers Ltd.","issue":"13","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2020,10,20]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Fluoroquinolones are one of the world\u2019s most valuable and popularly used categories of antimicrobial\nagents. This paper attempts to review the substantial progress of fluoroquinolones from\ntheir discovery to black box warning. Antibiotic drug choice will remain difficult in the presence of\nincreasing resistance, but the introduction of fluoroquinolones has created a new and exciting era in\nantimicrobial treatment. These are a synthetic heterogeneous group of compounds used in both hospital\nand community practices to treat numerous severe infections. The era of quinolone antibiotics began\nwith the serendipitous discovery of the quinolone prototype in 1962. The chronological development\nof fluoroquinolone reported that nalidixic acid was the first quinolone that gained popular choice\nfor the treatment of urinary tract infection. The subsequent agents like levofloxacin, ofloxacin, norfloxacin,\ngatifloxacin, moxifloxacin, clinafloxacin, sparfloxacin, and ciprofloxacin were derived\nthrough side chain and nuclear manipulation from basic pharmacophore. The fluoroquinolone motifs\nhave been found as a milestone, effective in certain infections that are respiratory tract infection, urinary\ntract infection, bone disorders, meningococcal and mycobacterial infections, sexually transmitted\ndiseases, skin infections, etc. Fluoroquinolones are first entirely man-made antibiotics that exhibit antibacterial\nactivity through the inhibition of topoisomerase II, topoisomerase IV and deoxyribonucleic\nacid gyrase, which is vital for chromosome replication and function. The post-marketing surveillance\npointed out the favorable side effects associated with fluoroquinolones such as phototoxicity, QT interval\nprolongation and anaphylaxis. The discovery, development and clinical use of fluoroquinolone\nantibiotics in the last century contributed to a decline in morbidity and mortality rates.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450121666200621193355","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T07:52:21Z","timestamp":1592812341000},"page":"1354-1370","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Fluoroquinolones: Blessings Or Curses"],"prefix":"10.2174","volume":"21","author":[{"given":"Priyanka P.","family":"Majalekar","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Appasaheb Birnale College of Pharmacy, Sangli. Shivaji University, Sangli \u2013 416416, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramodkumar J.","family":"Shirote","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Arvind Gavali College of Pharmacy, Satara Shivaji University, Satara- 415015, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5455\/njppp.2015.5.1604201547","volume":"5","author":"Chawan V.S.","year":"2015","unstructured":"Chawan V.S.; Gawand K.V.; Badwane S.V.; Fluoroquinolones in India- Are we prescribing it right: A cost variation study. Natl J Physiol Pharm Pharmacol 2015,5(4),306-308","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/jac\/dkg208","volume":"51","author":"Emmerson A.M.","year":"2003","unstructured":"Emmerson A.M.; Jones A.M.; The quinolones: decades of development and use. J Antimicrob Chemother 2003,51(Suppl. 1),13-20","journal-title":"J Antimicrob Chemother"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","volume":"22","author":"Redgrave L.S.","year":"2014","unstructured":"Redgrave L.S.; Sutton S.B.; Webber M.A.; Piddock L.J.; Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol 2014,22(8),438-445","journal-title":"Trends Microbiol"},{"key":"ref=4","first-page":"3735","volume":"10","author":"Majalekar P.P.","year":"2019","unstructured":"Majalekar P.P.; Shirote P.J.; Nalawade V.V.; Design, synthesis and comparative pharmacological assessment of novel Fluoroquinolone derivatives. Int J Pharm Sci Res 2019,10(8),3735-3740","journal-title":"Int J Pharm Sci Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1086\/516116","volume":"25","author":"Alangaden G.J.","year":"1997","unstructured":"Alangaden G.J.; Lerner S.A.; The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997,25(5),1213-1221","journal-title":"Clin Infect Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"908","DOI":"10.7326\/0003-4819-129-11_Part_1-199812010-00015","volume":"129","author":"Hooper D.C.","year":"1998","unstructured":"Hooper D.C.; Expanding uses of fluoroquinolones: opportunities and challenges. Ann Intern Med 1998,129(11),908-910","journal-title":"Ann Intern Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1542\/peds.2016-2706","volume":"138","author":"Jackson M.A.","year":"2016","unstructured":"Jackson M.A.; Schutze G.E.; COMMITTEE ON INFECTIOUS DISEASES. The use of systemic","journal-title":"Pediatrics"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3928\/0090-4481-20070601-09","volume":"36","author":"Murray T.S.","year":"2007","unstructured":"Murray T.S.; Baltimore R.S.; Pediatric uses of fluoroquinolone antibiotics. Pediatr Ann 2007,36(6),336-342","journal-title":"Pediatr Ann"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1586\/14787210.4.5.853","volume":"4","author":"Velissariou I.M.","year":"2006","unstructured":"Velissariou I.M.; The use of fluoroquinolones in children: recent advances. Expert Rev Anti Infect Ther 2006,4(5),853-860","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.17221\/7883-VETMED","volume":"46","author":"Sarkozy G.","year":"2001","unstructured":"Sarkozy G.; Quinolones: a class of antimicrobial agents. Vet Med 2001,46,257-274","journal-title":"Vet Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.7196\/SAMJ.2019.v109i6.14002","volume":"109","author":"Richards G.A.","year":"2019","unstructured":"Richards G.A.; Brink A.J.; Feldman C.; Rational use of the fluoroquinolones. S Afr Med J 2019,109(6),378-381","journal-title":"S Afr Med J"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/S1098-3597(03)90027-5","volume":"5","author":"Sprandel K.A.","year":"2003","unstructured":"Sprandel K.A.; Rodvold K.A.; Safety and tolerability of fluoroquinolones. Clin Cornerstone 2003,5(3)(Suppl. 3),S29-S36","journal-title":"Clin Cornerstone"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1155\/2002\/864789","volume":"13","author":"Mandell L.","year":"2002","unstructured":"Mandell L.; Tillotson G.; Safety of fluoroquinolones: An update. Can J Infect Dis 2002,13(1),54-61","journal-title":"Can J Infect Dis"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000057838","volume":"47","author":"Rubinstein E.","year":"2001","unstructured":"Rubinstein E.; History of quinolones and their side effects. Chemotherapy 2001,47(S3)(Suppl. 3),3-8","journal-title":"Chemotherapy"},{"key":"ref=15","first-page":"1","volume":"140","author":"Epstein A.B.","year":"2003","unstructured":"Epstein A.B.; Fluoroquinolones: the Next Generation. Review of Optometry 2003,140(1),1-7","journal-title":"Review of Optometry"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1056\/NEJMoa055191","volume":"354","author":"Park-Wyllie LY","year":"2006","unstructured":"Park-Wyllie LY; Juurlink DN; Kopp A;  Outpatient gatifloxacin therapy and dysglycemia in older adults Engl j med 2006,354(13),1352-61","journal-title":"Outpatient gatifloxacin therapy and dysglycemia in older adults Engl j med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1021\/jm501881c","volume":"58","author":"Bisacchi G.S.","year":"2015","unstructured":"Bisacchi G.S.; Origins of the Quinolone Class of Antibacterials: An Expanded \u201cDiscovery Story\u201d. J Med Chem 2015,58(12),4874-4882","journal-title":"J Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1128\/AAC.10.1.20","volume":"10","author":"Rohlfing S.R.","year":"1976","unstructured":"Rohlfing S.R.; Gerster J.R.; Kvam D.C.; Bioevaluation of the antibacterial flumequine for urinary tract use. Antimicrob Agents Chemother 1976,10(1),20-24","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1517\/13543784.8.2.123","volume":"8","author":"Dalhoff A.","year":"1999","unstructured":"Dalhoff A.; In vitro activities of quinolones. Expert Opin Investig Drugs 1999,8(2),123-137","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=20","author":"Bambeke FV","unstructured":"Bambeke FV; Michot JM; Eldere JV; Quinolones in 2005 European society of clinical Microbiology and Infectious Diseases 2005; 11: 256-80."},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0025-7125(05)70297-2","volume":"84","author":"Owens R.C.","year":"2000","unstructured":"Owens R.C.; Ambrose P.G.;  Clinical use of the Fluoroquinolones Antibiotic therapy 2000,84(60),1447-69","journal-title":"Clinical use of the Fluoroquinolones Antibiotic therapy"},{"key":"ref=22","unstructured":""},{"key":"ref=23","unstructured":""},{"key":"ref=24","unstructured":""},{"key":"ref=25","unstructured":""},{"key":"ref=26","unstructured":""},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg212","volume":"51","author":"Andersson M.I.","year":"2003","unstructured":"Andersson M.I.; MacGowan A.P.; Development of the quinolones. J Antimicrob Chemother 2003,51(S1)(Suppl. 1),1-11","journal-title":"J Antimicrob Chemother"},{"key":"ref=28","unstructured":""},{"key":"ref=29","unstructured":""},{"key":"ref=30","unstructured":""},{"key":"ref=31","unstructured":""},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0924-8579(00)00192-8","volume":"16","author":"Appelbaum P.C.","year":"2000","unstructured":"Appelbaum P.C.; Hunter P.A.; The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 2000,16(1),5-15","journal-title":"Int J Antimicrob Agents"},{"key":"ref=33","unstructured":""},{"key":"ref=34","unstructured":""},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0002-9343(87)90612-7","volume":"82(6)(2)","author":"Goldstein E.J.","year":"1987","unstructured":"Goldstein E.J.;  Norfloxacin, a fluoroquinolone antibacterial agent Alliance Academ Int Med 1987,82(6)(2),3-17","journal-title":"Norfloxacin, a fluoroquinolone antibacterial agent Alliance Academ Int Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/08941939.2013.808461","volume":"26","author":"Zaffiri L.","year":"2013","unstructured":"Zaffiri L.; Gardner J.; Toledo-Pereyra1 LH. History of antibiotics: From fuoroquinolones to Daptomycin (Part 2). J Invest Surg 2013,26,167-179","journal-title":"J Invest Surg"},{"key":"ref=37","unstructured":""},{"key":"ref=38","unstructured":""},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/S0149-2918(00)80053-3","volume":"22","author":"Bertino J.","year":"2000","unstructured":"Bertino J.; Fish D.; The safety profile of the fluoroquinolones. Clin Ther 2000,22(7),798-817","journal-title":"Clin Ther"},{"key":"ref=40","unstructured":""},{"key":"ref=41","unstructured":""},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1128\/CMR.2.4.378","volume":"2","author":"Wolfson J.S.","year":"1989","unstructured":"Wolfson J.S.; Hooper D.C.; Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989,2(4),378-424","journal-title":"Clin Microbiol Rev"},{"key":"ref=43","unstructured":""},{"key":"ref=44","unstructured":""},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.idc.2004.04.011","volume":"18","author":"O\u2019Donnell J.A.","year":"2004","unstructured":"O\u2019Donnell J.A.; Gelone S.P.; The newer fluoroquinolones. Infect Dis Clin North Am 2004,18(3),691-716,  x.","journal-title":"Infect Dis Clin North Am"},{"key":"ref=46","unstructured":""},{"key":"ref=47","first-page":"587","volume":"66","author":"Sharma P.C.","year":"2009","unstructured":"Sharma P.C.; Jain A.; Jain S.; Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm 2009,66(6),587-604","journal-title":"Acta Pol Pharm"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0924-8579(98)00059-4","volume":"10","author":"Naber K.G.","year":"1998","unstructured":"Naber K.G.; Adam D.; Classification of fluoroquinolones. Int J Antimicrob Agents 1998,10(4),255-257","journal-title":"Int J Antimicrob Agents"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/oxfordjournals.jac.a020889","volume":"46","author":"Ball P.","year":"2000","unstructured":"Ball P.; Quinolone generations: natural history or natural selection? J Antimicrob Chemother 2000,46(Suppl T1),17-24"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s12325-008-0107-x","volume":"25","author":"Scoper S.V.","year":"2008","unstructured":"Scoper S.V.; Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy. Adv Ther 2008,25(10),979-994","journal-title":"Adv Ther"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0002-9394(02)01334-X","volume":"133","author":"Mather R.","year":"2002","unstructured":"Mather R.; Karenchak L.M.; Romanowski E.G.; Kowalski R.P.; Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002,133(4),463-466","journal-title":"Am J Ophthalmol"},{"key":"ref=52","author":"Soni K.","year":"2012; 2(1): 42-53.","unstructured":"Soni K.;  Fluoroquinolones: chemistry action-A review Indo glob 2012; 2(1): 42-53.","journal-title":"Fluoroquinolones: chemistry action-A review Indo glob"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1099\/00222615-44-5-320","volume":"44","author":"Tillotson G.S.","year":"1996","unstructured":"Tillotson G.S.; Quinolones: structure-activity relationships and future predictions. J Med Microbiol 1996,44(5),320-324","journal-title":"J Med Microbiol"},{"key":"ref=54","first-page":"1","volume":"2","author":"Das R.","year":"2017","unstructured":"Das R.; Mehta D.K.; Sharma V.; Quinolones: Understanding the drug designing to combat drug resistance. Annals of Pharmacology and Pharmaceutics 2017,2(9),1-3","journal-title":"Annals of Pharmacology and Pharmaceutics"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics6040026","volume":"6","author":"Idowu T.","year":"2017","unstructured":"Idowu T.; Schweizer F.; Ubiquitous nature of fluoroquinolones: The oscillation between antibacterial and anticancer activities. Antibiotics (Basel) 2017,6(4),1-24","journal-title":"Antibiotics (Basel)"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2165\/00003495-199500492-00005","volume":"49","author":"Bryskier A.","year":"1995","unstructured":"Bryskier A.; Chantot J.F.; Classification and structure-activity relationships of fluoroquinolones. Drugs 1995,49(Suppl. 2),16-28","journal-title":"Drugs"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1021\/bi5000564","volume":"53","author":"Aldred K.J.","year":"2014","unstructured":"Aldred K.J.; Kerns R.J.; Osheroff N.; Mechanism of quinolone action and resistance. Biochemistry 2014,53(10),1565-1574","journal-title":"Biochemistry"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"44","DOI":"10.5808\/GI.2018.16.3.44","volume":"16","author":"Sood D.","year":"2018","unstructured":"Sood D.; Kumar N.; Singh A.; Sakharkar M.K.; Tomar V.; Chandra R.; Antibacterial and pharmacological evaluation of fluoroquinolones: A cheoinformatics approach. Genomics Inform 2018,16(3),44-51","journal-title":"Genomics Inform"},{"key":"ref=59","first-page":"S113","author":"Vincent A.","year":"2005","unstructured":"Vincent A.; The quinolones: Past, present, future, Supplement article, Overview of quinolone development. Clin Infect Dis 2005(41),S113-9"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/BF02347726","volume":"1","author":"Schimizu M.","year":"1995","unstructured":"Schimizu M.; Quinolone antibacterial agents: Their past, present, future. J Infect Chemother 1995,1,16-29","journal-title":"J Infect Chemother"},{"key":"ref=61","first-page":"455","volume":"65","author":"Oliphant C.M.","year":"2002","unstructured":"Oliphant C.M.; Green G.M.; Quinolones: a comprehensive review. Am Fam Physician 2002,65(3),455-464","journal-title":"Am Fam Physician"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14777\/kjutii.2015.10.1.1","volume":"10","author":"Ko Y.H.","year":"2015","unstructured":"Ko Y.H.; Song P.H.; Current updates in and pharmacodynamics of fluoroquinolones. Korean J Urogenit Tract Infect Inflamm 2015,10(1),1-6","journal-title":"Korean J Urogenit Tract Infect Inflamm"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1086\/514623","volume":"27","author":"Lode H.","year":"1998","unstructured":"Lode H.; Borner K.; Koeppe P.; Pharmacodynamics of fluoroquinolones. Clin Infect Dis 1998,27(1),33-39","journal-title":"Clin Infect Dis"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/BF01967014","volume":"10","author":"Norrby S.R.","year":"1991","unstructured":"Norrby S.R.; Side-effects of quinolones: comparisons between quinolones and other antibiotics. Eur J Clin Microbiol Infect Dis 1991,10(4),378-383","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4103\/UA.UA_104_19","volume":"11","author":"Abou Heidar N.F.","year":"2019","unstructured":"Abou Heidar N.F.; Degheili J.A.; Yacoubian A.A.; Khauli R.B.; Management of urinary tract infection in women: A practical approach for everyday practice. Urol Ann 2019,11(4),339-346","journal-title":"Urol Ann"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0924-8579(00)00362-9","volume":"17","author":"Naber K.G.","year":"2001","unstructured":"Naber K.G.; Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 2001,17(4),331-341","journal-title":"Int J Antimicrob Agents"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/BF01967009","volume":"10","author":"Andriole V.T.","year":"1991","unstructured":"Andriole V.T.; Use of quinolones in treatment of prostatitis and lower urinary tract infections. Eur J Clin Microbiol Infect Dis 1991,10(4),342-350","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"S1321","DOI":"10.1093\/clinids\/11.Supplement_5.S1321","volume":"II5","author":"Naber K.G.","year":"1989","unstructured":"Naber K.G.;  Use of Quinolones in Urinary Tract Infections and Prostatitis Inf Dis 1989,II5,S1321-S1337","journal-title":"Use of Quinolones in Urinary Tract Infections and Prostatitis Inf Dis"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1517\/13543784.10.2.213","volume":"10","author":"Blondeau J.M.","year":"2001","unstructured":"Blondeau J.M.; Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections. Expert Opin Investig Drugs 2001,10(2),213-237","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2165\/00003495-200565070-00004","volume":"65","author":"Shams W.E.","year":"2005","unstructured":"Shams W.E.; Evans M.E.; Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. Drugs 2005,65(7),949-991","journal-title":"Drugs"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","volume":"279","author":"Zimmerli W.","year":"1537","unstructured":"Zimmerli W.; Widmer A.F.; Blatter M.; Role of rifampin for treatment of orthopedic implantrelated staphylococcal infections: A randomized controlled trial J Am Med Ass 1537,279(19),1537-1541","journal-title":"J Am Med Ass"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa1710926","volume":"380","author":"Li H.K.","year":"2019","unstructured":"Li H.K.; Rombach I.; Zambellas R.; OVIVA Trial Collaborators. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med 2019,380(5),425-436","journal-title":"N Engl J Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.02516-18","volume":"63","author":"Sarathy J.","year":"2019","unstructured":"Sarathy J.; Blanc L.; Alvarez-Cabrera N.; Fluoroquinolones efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations. Antimicrob Agents Chemother 2019,63(5),1-16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1179\/joc.1999.11.1.50","volume":"11","author":"Edlund C.","year":"1999","unstructured":"Edlund C.; Nord C.E.; Ecological effect of gatifloxacin on the normal human intestinal microflora. J Chemother 1999,11(1),50-53","journal-title":"J Chemother"},{"key":"ref=75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001838","volume":"12","author":"Chen M.","year":"2015","unstructured":"Chen M.; Guo Q.; Wang Y.; Shifts in the antibiotic Susceptibility, Serogroups, and clonal complexes of Neisseria meningitidis in shanghai, china: A time trend analysis of the pre-quinolone and quinolone eras. PLoS Med 2015,12(6)","journal-title":"PLoS Med"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11908-003-0011-0","volume":"5","author":"Cottagnoud P","year":"2003","unstructured":"Cottagnoud P; Taube MG;  Fluoroquinolones in the treatment of meningitis Cur infect Dis 2003,5(329),6","journal-title":"Fluoroquinolones in the treatment of meningitis Cur infect Dis"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ijantimicag.2008.08.004","volume":"33","author":"Sendzik J.","year":"2009","unstructured":"Sendzik J.; Lode H.; Stahlmann R.; Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents 2009,33(3),194-200","journal-title":"Int J Antimicrob Agents"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.curtheres.2003.11.003","volume":"64","author":"Ball P.","year":"2003","unstructured":"Ball P.; Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review. Curr Ther Res Clin Exp 2003,64(9),646-661","journal-title":"Curr Ther Res Clin Exp"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/jac\/dkg209","volume":"51","author":"Ball P.","year":"2003","unstructured":"Ball P.; Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 2003,51(Suppl. 1),21-27","journal-title":"J Antimicrob Chemother"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4085\/1062-6050-49.2.09","volume":"49","author":"Lewis T.","year":"2014","unstructured":"Lewis T.; Cook J.; Fluoroquinolones and tendinopathy: a guide for athletes and sports clinicians and a systematic review of the literature. J Athl Train 2014,49(3),422-427","journal-title":"J Athl Train"},{"key":"ref=81","first-page":"1","volume":"2015","author":"Golomb B.A.","year":"2015","unstructured":"Golomb B.A.; Koslik H.J.; Redd A.J.; Fluoroquinolone-induced serious, persistent, multisymptom adverse effects. BMJ Case Rep 2015,2015,1-10","journal-title":"BMJ Case Rep"},{"key":"ref=82","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010077","volume":"5","author":"Daneman N.","year":"2015","unstructured":"Daneman N.; Lu H.; Redelmeier D.A.; Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open 2015,5(11)","journal-title":"BMJ Open"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3345\/kjp.2013.56.5.196","volume":"56","author":"Choi S.H.","year":"2013","unstructured":"Choi S.H.; Kim E.Y.; Kim Y.J.; Systemic use of fluoroquinolone in children. Korean J Pediatr 2013,56(5),196-201","journal-title":"Korean J Pediatr"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics8030104","volume":"8","author":"Mathews B.","year":"2019","unstructured":"Mathews B.; Thalody A.A.; Miraj S.S.; Kunhikatta V.; Rao M.; Saravu K.; Adverse Effects of Fluoroquinolones: A retrospective cohort study in a south indian tertiary healthcare facility. Antibiotics (Basel) 2019,8(3),1-17","journal-title":"Antibiotics (Basel)"},{"key":"ref=85","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8023935","author":"Michalak K.","year":"2017","unstructured":"Michalak K.; Sobolewska-W\u0142odarczyk A.; W\u0142odarczyk M.; Sobolewska J.; Wo\u017aniak P.; Sobolewski B.; Treatment of the fluoroquinolone - associated disability: The pathobiochemical implications. Oxid Med Cell Longev 2017","journal-title":"Oxid Med Cell Longev"},{"key":"ref=86","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008273","volume":"96","author":"Liu X.","year":"2017","unstructured":"Liu X.; Ma J.; Huang L.; Fluoroquinolones increase the risk of serious arrhythmias: A systematic review and meta-analysis. Medicine (Baltimore) 2017,96(44)","journal-title":"Medicine (Baltimore)"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40264-018-0751-2","volume":"42","author":"Gorelik E.","year":"2019","unstructured":"Gorelik E.; Masarwa R.; Perlman A.; Fluoroquinolones and cardiovascular risk: A systematic review, meta-analysis and network meta-analysis. Drug Saf 2019,42(4),529-538","journal-title":"Drug Saf"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.mcna.2011.03.006","volume":"95","author":"Bolon M.K.","year":"2011","unstructured":"Bolon M.K.;  The newer fluoroquinolones Med clin N Am 2011,95,793-817","journal-title":"The newer fluoroquinolones Med clin N Am"},{"key":"ref=89","first-page":"371","volume":"8","author":"Sarro A.","year":"2001","unstructured":"Sarro A.; Sarro G.;  Adverse reactions to fluoroquinolones  An overview on mechanistic aspects Cur med chem 2001,8,371-84","journal-title":"Adverse reactions to fluoroquinolones  An overview on mechanistic aspects Cur med chem"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.japh.2018.08.011","volume":"59","author":"Molnar D.M.","year":"2019","unstructured":"Molnar D.M.; Kremzner M.E.; Fluoroquinolones: A hot topic for pharmacists and the food and drug administration\u2019s division of drug information. J Am Pharm Assoc 2019,59(1),13-16","journal-title":"J Am Pharm Assoc"},{"key":"ref=91","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003679","volume":"95","author":"Fernandez T.D.","year":"2016","unstructured":"Fernandez T.D.; Ariza A.; Palomares. Hypersensitivity to fluoroquinolones. Med (Baltimore) 2016,95(23)","journal-title":"Med (Baltimore)"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4103\/2230-973X.100040","volume":"2","author":"Khurana G.","year":"2012","unstructured":"Khurana G.; Arora S.; Pawar P.K.; Ocular insert for sustained delivery of gatifloxacin sesquihydrate: Preparation and evaluations. Int J Pharm Investig 2012,2(2),70-77","journal-title":"Int J Pharm Investig"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7897\/2230-8407.041009","volume":"4","author":"Rajalakshmi R.","year":"2013","unstructured":"Rajalakshmi R.; Padmaja C.; Formulation and assessment of gemifloxacin mesylate ocular in situ gelling system. Int Res J Pharm 2013,4(10),33-38","journal-title":"Int Res J Pharm"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4103\/2230-973X.133057","volume":"4","author":"Gaikwad V.D.","year":"2014","unstructured":"Gaikwad V.D.; Yadav V.D.; Gaikwad M.D.; Novel sustained release and swellable gastroretentive dosage form for ciprofloxacin hydrochloride. Int J Pharm Investig 2014,4(2),88-92","journal-title":"Int J Pharm Investig"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5731\/pdajpst.2011.00685","volume":"65","author":"Guguloth M.","year":"2011","unstructured":"Guguloth M.; Bomma R.; Veerabrahma K.; Development of sustained release floating drug delivery system for norfloxacin: in vitro and in vivo evaluation. PDA J Pharm Sci Technol 2011,65(3),198-206","journal-title":"PDA J Pharm Sci Technol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijpharm.2006.02.038","volume":"316","author":"Chavanpatil M.D.","year":"2006","unstructured":"Chavanpatil M.D.; Jain P.; Chaudhari S.; Shear R.; Vavia P.R.; Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Int J Pharm 2006,316(1-2),86-92","journal-title":"Int J Pharm"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4103\/0975-7406.160015","volume":"7","author":"Gupta H.","year":"2015","unstructured":"Gupta H.; Malik A.; Khar R.K.; Ali A.; Bhatnagar A.; Mittal G.; Physiologically active hydrogel (in situ gel) of sparfloxacin and its evaluation for ocular retention using gamma scintigraphy. J Pharm Bioallied Sci 2015,7(3),195-200","journal-title":"J Pharm Bioallied Sci"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jsps.2014.02.009","volume":"22","author":"El-Zahaby S.A.","year":"2014","unstructured":"El-Zahaby S.A.; Kassem A.A.; El-Kamel A.H.; Design and evaluation of gastroretentive levofloxacin floating mini-tablets-in-capsule system for eradication of Helicobacter pylori. Saudi Pharm J 2014,22(6),570-579","journal-title":"Saudi Pharm J"},{"key":"ref=99","first-page":"1","volume":"7","author":"Satyanandam S.","year":"2015","unstructured":"Satyanandam S.; Murala S.; PH-Induced in situ gelling system of lomefloxacin for sustained ocular delivery. Int J Pharm Sci Drug Res 2015,7(5),1-4","journal-title":"Int J Pharm Sci Drug Res"},{"key":"ref=100","unstructured":""},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"a816","DOI":"10.1136\/bmj.a816","volume":"337","author":"Tanne J.H.","year":"2008","unstructured":"Tanne J.H.; FDA adds \u201cblack box\u201d warning label to fluoroquinolone antibiotics. BMJ 2008,337(7662),a816","journal-title":"BMJ"},{"key":"ref=102","unstructured":""}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/183012","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/183012\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/183012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T19:03:22Z","timestamp":1615575802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/183012\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":102,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,10,20]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450121666200621193355","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}